Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) was devalued by  Zacks Research  from a “get” rating to a “hold” score in a research note provided to financiers on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on uncovering and also creating tiny particle drug candidates to treat cancer. The Firm‘s products under different phases of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts also recently talked about the firm. Noble Financial reissued a “get” score and issued a $11.00 cost purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “acquire” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day relocating typical cost of $2.90 and also a two-hundred day relocating average cost of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) revenues per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% and also an adverse internet margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, contrasted to the consensus price quote of $0.06 million. During the exact same quarter in the prior year, the firm uploaded ($ 0.45) EPS. As a group, research experts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A number of hedge funds have recently bought and sold shares of ONTX. GSA Funding Partners LLP purchased a new position in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a new position in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC got a new placement in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a brand-new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as other institutional investors have 13.36% of the business’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which takes part in the recognition as well as development of oncology therapeutics. It focuses on uncovering as well as establishing little particle medicine prospects to treat cancer cells. The firm was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a complimentary copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, go to Zacks.com.

This instant information alert was generated by narrative scientific research innovation as well as economic data from Market in order to give visitors with the fastest and most accurate coverage. This tale was assessed by Market’s editorial team prior to publication. 



Prior to you think about Onconova Therapeutics, you’ll wish to hear this.

Market tracks Wall Street’s premier as well as ideal carrying out research experts and also the stocks they advise to their customers each day. Market has actually recognized the five stocks that cover analysts are quietly murmuring to their clients to buy currently before the broader market catches on … and Onconova Therapeutics had not been on the list.

While Onconova Therapeutics currently has a “Buy” ranking among experts, top-rated experts think these 5 stocks are better buys.